Compare ARI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARI | ANL |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 998.8M |
| IPO Year | 2009 | 2022 |
| Metric | ARI | ANL |
|---|---|---|
| Price | $6.42 | $10.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.00 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 3.3M | 308.7K |
| Earning Date | 11-02-2026 | 08-14-2026 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | ★ 183.51 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $271,589,000.00 | N/A |
| Revenue This Year | N/A | $243.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.11 | $0.88 |
| 52 Week High | $11.24 | $17.25 |
| Indicator | ARI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 35.97 |
| Support Level | $6.11 | $8.96 |
| Resistance Level | $6.47 | $12.49 |
| Average True Range (ATR) | 0.11 | 1.37 |
| MACD | 0.03 | -0.35 |
| Stochastic Oscillator | 84.13 | 5.05 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.